FDA clears Vesalio’s latest mechanical thrombectomy device
August 13, 2026
Vesalio’s pVasc NET mechanical thrombectomy device integrates clot-capture technology to retain clot fragments during retrieval.
Vesalio’s pVasc NET mechanical thrombectomy device integrates clot-capture technology to retain clot fragments during retrieval.
The SimpleScreen test is designed to detect early lung cancer signals from a standard blood sample.
FastWave Medical earned FDA investigational device exemption (IDE) approval for its next-generation intravascular lithotripsy (IVL) technology, the company announced today.
HENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announces that results utilizing its lateral flow prototype are highly correlated with results utilizing Volition’s established automated Nu.Q® NETs test in critically ill sepsis patients1 , thereby expanding beyond centralized laboratory testing.
Some of medicine’s smallest patients can present its biggest imaging challenges. An infant’s heart can be as small as a walnut, beating rapidly inside a body that will change dramatically as the child grows. Yet much of the equipment used in MRI comes in standard sizes better suited to adult bodies, and customized versions can cost thousands of dollars and take months or even years to manufacture.
Now, a team led by Wei Gao, a professor in Caltech’s Cherng Department of Medical Engineering, has developed a stick-on patch capable of gathering lipid measurements by analyzing sweat. And it can do so not just once but continuously.
The device will be sold initially in the US and Canada, with further submissions planned in additional markets.
Wandercraft, a Paris-based robotics company, announced that the FDA has granted clearance for Eve, its personal self-balancing exoskeleton designed to support upright mobility.
FRANKLIN LAKES, N.J., Aug. 12, 2026 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias.
MILAN, Aug. 11, 2026 /PRNewswire/ — Bracco Imaging today announced that VueJect®, its first dedicated ultrasound contrast delivery system engineered to support cardiology imaging specifically, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and authorization from Health Canada.